You are herePharma News

Pharma News

Meditation lowers pain, anxiety in breast cancer biopsy

Meditation eases anxiety, fatigue and pain for women undergoing breast cancer biopsies, new research says.Researchers from the Duke Cancer Institute in Durham, US found that during such period even music is effective, but only to a lesser extent.

BMI a wrong measure of health: Study

Using body mass index (BMI) to gauge health is a wrong practice as it is a deeply flawed measure, reveals a study while adding that BMI should not be the primary goal for maintaining good health.

How inflammation in the gut ups risk of colon cancer

c in the gut increases the risk of colon cancer the second-largest cause of cancer death in the US by as much as 500 percent, says a new study.

Interlink between Chidhood ADHD, gender and obesity

Children with childhood attention deficit hyperactivity disorder (ADHD) the most commonly diagnosed mental disorder of children are at a high risk of developing obesity, a new study has found.

Viral infections can contribute to mental deterioration

Chronic viral infections like CMV, HSV-2 or toxoplasma can contribute to subtle mental deterioration in apparently healthy older adults, a study has revealed.

Abbott To Acquire Alere

Abbott and Alere Inc announced a definitive agreement for Abbott to acquire Alere, significantly advancing Abbott's global diagnostics presence and leadership. Under the terms of the agreement, Abbott will pay $56 per common share at a total expected equity value of $5.8 billion. Once the transaction is completed, Abbott will become the leading diagnostics provider of point of care testing. Abbott's total diagnostics sales will exceed $7 billion after the close.

FDA Grants Conatus Fast Track Designation for Development of Emricasan in NASH Cirrhosis

Conatus Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company's emricasan development program for the treatment of liver cirrhosis caused by nonalcoholic steatohepatitis (NASH).

Mersana Therapeutics and Takeda Expand Partnership

Mersana Therapeutics and Takeda Pharmaceutical Company Limited  announced that they have entered a new strategic partnership granting Takeda rights to Mersana’s lead product candidate, XMT-1522, outside the United States and Canada. The deal also expands an existing collaboration between the companies to provide Takeda with additional access to Mersana’s Fleximer® antibody-drug conjugate (ADC) platform and grants Mersana an option at the end of Phase 1 to co-develop and co-commercialize one of these programs in the United States. In addition, the companies will co-develop new payloads for use with ADCs.

XMT-1522 is an investigational, Fleximer-based ADC therapy that targets HER2-expressing tumors, including breast, gastric and non-small cell lung cancers. Preclinical data suggest that XMT-1522 may have anti-tumor activity in patients with HER2 low-expressing cancers as well as in patients with HER2 high-expressing cancers that do not respond to currently available HER2-targeting therapies. Mersana anticipates filing an Investigational New Drug application (IND) for XMT-1522 with the U.S. Food and Drug Administration (FDA) in mid-2016.

TAGRISSO™ approved in EU as first-in-class treatment for patients with EGFR T790M mutation-positive NSCLC

AstraZeneca  announced that the European Commission (EC) has granted conditional marketing authorisation for TAGRISSO™ (AZD9291, osimertinib) 80mg once-daily tablets for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).

Bracco diagnostics inc. Get first u.s. Fda approval for barium-based product

Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, announced the U.S. Food and Drug Administration (FDA) approved E-Z-HD for use in double-contrast radiographic examinations of the esophagus, stomach.